150,000 Shares in Kura Oncology, Inc. (NASDAQ:KURA) Bought by Velan Capital Investment Management LP

Velan Capital Investment Management LP bought a new position in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 150,000 shares of the company's stock, valued at approximately $1,306,000. Kura Oncology makes up approximately 1.1% of Velan Capital Investment Management LP's portfolio, making the stock its 16th largest position. Velan Capital Investment Management LP owned 0.19% of Kura Oncology at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in KURA. Virtus ETF Advisers LLC increased its stake in Kura Oncology by 71.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company's stock valued at $64,000 after purchasing an additional 3,061 shares during the last quarter. Harbor Advisors LLC purchased a new position in shares of Kura Oncology in the 4th quarter valued at $87,000. E Fund Management Co. Ltd. acquired a new stake in Kura Oncology during the 4th quarter worth $90,000. Corton Capital Inc. purchased a new stake in Kura Oncology in the fourth quarter valued at $99,000. Finally, Optimize Financial Inc purchased a new stake in Kura Oncology in the fourth quarter valued at $100,000.

Kura Oncology Stock Performance

Shares of NASDAQ:KURA traded up $0.04 during midday trading on Thursday, hitting $6.24. The stock had a trading volume of 843,603 shares, compared to its average volume of 1,186,660. Kura Oncology, Inc. has a 1 year low of $5.41 and a 1 year high of $23.48. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock has a 50 day moving average price of $6.33 and a two-hundred day moving average price of $8.53. The company has a market capitalization of $540.23 million, a PE ratio of -2.64 and a beta of 0.50.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15). The company had revenue of $14.11 million for the quarter, compared to analysts' expectations of $39.08 million. As a group, equities analysts predict that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

KURA has been the topic of a number of research analyst reports. Wedbush reiterated an "outperform" rating and set a $36.00 target price on shares of Kura Oncology in a research report on Tuesday, April 8th. BTIG Research downgraded Kura Oncology from a "buy" rating to a "neutral" rating in a research note on Thursday, February 6th. Wall Street Zen cut Kura Oncology from a "buy" rating to a "hold" rating in a research note on Friday, May 2nd. JMP Securities reissued a "market outperform" rating and issued a $28.00 price objective on shares of Kura Oncology in a report on Tuesday, April 29th. Finally, Mizuho reduced their price target on shares of Kura Oncology from $32.00 to $30.00 and set an "outperform" rating for the company in a research report on Monday. Four investment analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $24.50.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.